NL-OMON39021
Completed
Phase 4
An international collaborative study to discontinue Imatinib/Glivec® in pediatric CML patients with sustained complete molecular response - STOPIMAPED
Stichting Kinderoncologie Nederland0 sites6 target enrollmentStarted: TBDLast updated:
Overview
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Stichting Kinderoncologie Nederland
- Enrollment
- 6
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 2 to 17 (—)
Inclusion Criteria
- •Pediatric CML patients treated with Imatinib having achieved and maintained complete molecular remission for at least 2 years.
- •Informed consent needs to be signed.
Exclusion Criteria
- •Non\-CML patients, or CML patients with complete cytogenetic reponse but with a moderate molecular response.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
An international collaborative study to discontinue Imatinib/Glivec® in pediatric CML patients with sustained complete molecular response(STOPIMAPED)Chronic Myeloid Leukemia pediatric patients treated with Imatinib having achieved and maintained complete molecular remission for at least 2 years.Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-006239-44-NLDutch Childhood Oncology Group60
Not yet recruiting
Not Applicable
An international collaborative study to discontinue Imatinib/Glivec® in pediatric CML patients with sustained complete molecular response (STOPIMAPED).CMLchildrenstop Imatinib/Glivec®complete molecular responseNL-OMON23324SKION/DCOG (Stichting Kinderoncologie Nederland)Leyweg 2992545CJ Den Haag60
Completed
Phase 1
Pilot study "International collaborative investigation of underlying technology to develop information exchange platform with hairdresser and barber for successful aging in Thailand and Japan"Shop owner and customers in hairdresser/barberJPRN-UMIN000023733Akita University12
Recruiting
Phase 1
International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastinestandard risk ALK-positive anaplastic large cell lymphoma (ALCL)Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2022-501454-11-00GPOH gGmbH132
Recruiting
Phase 3
International cooperative prospective study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of VinblastineDRKS00023541Gesellschaft für pädiatrische Hämatologie und Onkologie (GPOH) gGmbH106